Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

About Us

At a glance

Shield Therapeutics is a commercial stage specialty pharmaceutical company.

Delivering innovative speciality pharmaceuticals to address significant unmet needs in the treatment of iron deficiency and hyperphosphatemia.

Our lead product Feraccru®/Accrufer® is a novel, stable, non-salt based oral therapy and is approved in the United States, European Union, UK and Switzerland for the treatment of iron deficiency with or without anaemia in adults.

In Europe the product is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA the product is marketed as Accrufer®.

We also have an exclusive licence agreement with ASK Pharm who will lead development and commercialisation in China, Hong Kong, Macau and Taiwan.

We have an active product pipeline and partnering opportunities.

 

 

What sets us apart

  • Lead product Feraccru® / Accrufer®

    Our lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid 2030s.

    In Europe the product is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA – where the product benefits from NCE exclusivity until 2024 – it is marketed as Accrufer®.

    In China we are working closely with ASK Pharm who will lead development and commercialisation in this region.

  • Large market opportunities with unmet needs

    The US is the world’s largest and most attractively reimbursed pharmaceutical market. There are at least 10 million patients in the USA who suffer from iron deficiency anaemia and potentially two to three times this number require treatment for iron deficiency. Our lead product is approved by the FDA and is marketed in the US as Accrufer®.

    In Europe our lead product is marketed as Feraccru® and is available to treat the estimated 40 million people with iron deficiency, representing another significant commercial opportunity.

  • Experienced management team with extensive expertise

    The skilled senior management team and board of directors provide strong leadership for the Company’s future growth.

  • Strong intellectual property protection

    The Group’s assets are supported by a suite of robust intellectual property rights including key patents in major markets. Feraccru® / Accrufer®, for the treatment of Iron Deficiency with or without anaemia in adults benefits from data exclusivity protection in Europe and the USA and has exclusive IP rights until the mid-2030’s.

Reasons to invest in Shield.

Iron deficiency is a large, diverse and undertreated market

Iron deficiency is a large, diverse and undertreated market

Existing oral and IV therapies have significant drawbacks, including poor tolerability and effectiveness (oral), and high cost, inconvenience and risk of iron overload (IV)

Existing oral and IV therapies have significant drawbacks, including poor tolerability and effectiveness (oral), and high cost, inconvenience and risk of iron overload (IV)

Feraccru®/Accrufer® has a unique oral formulation and has been shown to be effective, convenient and well-tolerated

Feraccru®/Accrufer® has a unique oral formulation and has been shown to be effective, convenient and well-tolerated

Shield has recently launched Accrufer® in the US, targeting a market of at least 10 million iron deficiency patients

Shield has recently launched Accrufer® in the US, targeting a market of at least 10 million iron deficiency patients

Accrufer® has a 90% gross margin and the potential to reach $300m-$400m sales revenue in the US

Accrufer® has a 90% gross margin and the potential to reach $300m-$400m sales revenue in the US

Feraccru®/Accrufer® has patent protection until 2035

Feraccru®/Accrufer® has patent protection until 2035

Downside protection has been achieved through European and Chinese licence transactions

Downside protection has been achieved through European and Chinese licence transactions

Meet the team

Our people are committed, effective and determined to succeed. Everyone is valued.

Chief Executive Officer

Greg Madison

Chief Financial Officer

Hans-Peter Rudolf

President Shield US and Chief Commercial Officer

Brian Groch

Chief Medical Officer

Jose A. Menoyo MD

General Counsel and Company Secretary

Lucy Huntington-Bailey

VP Commercial Operations

David Childs

VP Regulatory Affairs and Quality

Dr Jackie Mitchell